Brooklyn Immuno Therapeutics, Inc. BTX
We take great care to ensure that the data presented and summarized in this overview for Brooklyn ImmunoTherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BTX
View allLatest Institutional Activity in BTX
Top Purchases
Top Sells
About BTX
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Insider Transactions at BTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 29
2024
|
Charles Cherington > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,819,546
+14.5%
|
$0
$0.5 P/Share
|
|
Oct 29
2024
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
13,252,112
+25.3%
|
-
|
|
Jun 21
2024
|
Sandra M Gurrola Sr. VP of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-13.19%
|
$180
$1.94 P/Share
|
|
Jun 21
2024
|
Sandra M Gurrola Sr. VP of Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
437
+24.25%
|
-
|
|
Jun 21
2023
|
Sandra M Gurrola Sr. VP of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-16.17%
|
$358
$2.48 P/Share
|
|
Jun 21
2023
|
Sandra M Gurrola Sr. VP of Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
438
+28.35%
|
-
|
|
Dec 02
2022
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
261,756
+31.99%
|
$785,268
$3.28 P/Share
|
|
Dec 02
2022
|
Nicholas Jason Singer |
BUY
Open market or private purchase
|
Indirect |
283,286
+40.57%
|
$849,858
$3.28 P/Share
|
|
Dec 02
2022
|
John D Halpern > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
335,920
+42.69%
|
$1,007,760
$3.28 P/Share
|
|
Sep 20
2022
|
Roger Sidhu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,163
+50.0%
|
-
|
|
Jun 28
2022
|
Kevin D Amour Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,077
-34.58%
|
$0
$0.55 P/Share
|
|
Jun 28
2022
|
Kevin D Amour Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,573
+50.0%
|
-
|
|
Jun 21
2022
|
Sandra M Gurrola Sr. VP of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,586
-21.15%
|
$0
$0.48 P/Share
|
|
Jun 21
2022
|
Sandra M Gurrola Sr. VP of Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+34.04%
|
-
|
|
Jul 14
2021
|
George P Denny Iii > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1
+25.0%
|
$11
$11.99 P/Share
|
|
Jul 09
2021
|
George P Denny Iii > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1
+33.33%
|
$14
$14.11 P/Share
|
|
Jul 08
2021
|
George P Denny Iii > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1
+50.0%
|
$14
$14.35 P/Share
|
|
Jul 06
2021
|
George P Denny Iii > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,000
-1.55%
|
$1,200,000
$16.06 P/Share
|
|
Jun 17
2021
|
Charles Cherington > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-1.64%
|
$3,200,000
$16.02 P/Share
|
|
Jun 16
2021
|
Charles Cherington > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-3.18%
|
$3,000,000
$15.73 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 2.82M shares |
|---|---|
| Open market or private purchase | 13.3M shares |
| Exercise of conversion of derivative security | 437 shares |
| Payment of exercise price or tax liability | 180 shares |
|---|